SCHEMBL2860480

SCHEMBL2860480

O=[C]c1cccc2c1C=CC2

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL286721 0.80 CA1 (0.44) CA1CA2
SCHEMBL21694388 0.80 PRKCQ (0.36) CA1CA2
SCHEMBL1082849 0.79 CYP3A4 (0.37)
SCHEMBL28926913 0.78 CA1 (0.43) CA1CA2
SCHEMBL277191 0.74 CA1 (0.33) CA1CA2
SCHEMBL7647041 0.69
SCHEMBL6643583 0.68 CYP1A2 (0.37) CA1CA2
SCHEMBL319418 0.68 CYP2A6 (0.35) CA1CA2
SCHEMBL277192 0.68 BCL2L1 (0.39) CA1CA2
SCHEMBL1324313 0.68 CA1 (0.32) CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9777000-B2 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2017-10-03 US disclosed
US-20160347751-A1 NOVEL PYRAZOLE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2016-12-01 US disclosed
US-9458157-B2 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2016-10-04 US disclosed
US-9453015-B2 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2016-09-27 US disclosed
US-9440970-B2 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2016-09-13 US disclosed
EP-2963037-A1 NOVEL PYRAZOLE DERIVATIVE Mochida Pharmaceutical Co., Ltd. (JP) 2016-01-06 EP disclosed
US-20150166536-A1 NOVEL PYRAZOLE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-06-18 US disclosed
US-20150132327-A1 NOVEL PYRAZOLE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-05-14 US disclosed
US-20150133448-A1 NOVEL PYRAZOLE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-05-14 US disclosed
US-8980888-B2 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-03-17 US disclosed
US-7700789-B2 Heterogeneous catalyst and process for producing oxirane compound with the catalyst NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-04-20 US disclosed
EP-1632291-B1 HETEROGENEOUS CATALYST AND PROCESS FOR PRODUCING OXIRANE COMPOUND WITH THE CATALYST NISSAN CHEMICAL IND LTD (JP) 2009-12-16 EP disclosed
EP-2106855-A1 Heterogeneous catalyst and process for producing oxirane compound with the catalyst Nissan Chemical Industries, Ltd. (JP) 2009-10-07 EP disclosed
US-20090082583-A1 Heterogeneous catalyst and process for producing oxirane compound with the catalyst NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-03-26 US disclosed
US-20070093667-A1 Heterogeneous catalyst and process for producing oxirane compound with the catalyst NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2007-04-26 US disclosed
EP-1632291-A1 HETEROGENEOUS CATALYST AND PROCESS FOR PRODUCING OXIRANE COMPOUND WITH THE CATALYST Nissan Chemical Industries, Ltd. (JP) 2006-03-08 EP disclosed
US-20050282730-A1 Thrombopoetin receptor activator and process for producing the same NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2005-12-22 US disclosed
EP-1552828-A1 THROMBOPOETIN RECEPTOR ACTIVATOR AND PROCESS FOR PRODUCING THE SAME Nissan Chemical Industries, Ltd. (JP) 2005-07-13 EP disclosed
US-4438277-A Hydronaphthalene derivatives SANKYO COMPANY, LIMITED (JP) 1984-03-20 US disclosed
US-4361515-A Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use SANKYO COMPANY, LIMITED (JP) 1982-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093667-A1 Heterogeneous catalyst and process for producing oxirane compound with the catalyst OXGR1, OXER1, OGFOD1 CA1 181/4885CA2 232/4885
US-20150166536-A1 NOVEL PYRAZOLE DERIVATIVE PDE10A, PDE3A, PDE5A CA1 3079/4885CA2 2605/4885
US-20090082583-A1 Heterogeneous catalyst and process for producing oxirane compound with the catalyst OXGR1, OGFOD1, OGDH CA1 196/4885CA2 229/4885
US-20050282730-A1 Thrombopoetin receptor activator and process for producing the same PDGFRA, PTAFR, TBXA2R CA1 4458/4885CA2 4434/4885
US-20160347751-A1 NOVEL PYRAZOLE DERIVATIVE PDE10A, PDE3A, PDE5A CA1 3079/4885CA2 2605/4885
US-20150133448-A1 NOVEL PYRAZOLE DERIVATIVE PDE10A, PDE3A, PDE5A CA1 3079/4885CA2 2605/4885
US-20150132327-A1 NOVEL PYRAZOLE DERIVATIVE PDE10A, PDE3A, PDE5A CA1 3079/4885CA2 2605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.